Skip to main content
. 2011 Jan 10;29(7):789–796. doi: 10.1200/JCO.2010.32.8021

Fig 4.

Fig 4.

Effect of TG101348 therapy on JAK2 V617F allele burden. Box plot representation of JAK2 V617F allele burden data (A,B) for all mutation-positive patients (n = 51) and (C,D) for the subgroup with baseline allele burden greater than 20% (n = 23). The y-axis represents the JAK2 V617F allele burden from 1.0 (100%) to 0.0 (0%).The change in JAK2 V617F allele burden per cycle of treatment (up to end of cycle 12; ie, C13D1) compared with prestudy baseline is shown (A,C) for the two groups. (B,D) The change at the end of cycle 6 (ie, C7D1) and cycle 12. A significant decrease in JAK2 V617F allele burden compared with prestudy baseline was observed at the end of cycle 6 (B) for the mutation-positive group (P = .04) and (D) for the subgroup with baseline allele burden greater than 20% (P = .002); a similar significant decrease was seen at the end of cycle 12 (B) for the former (P = .01) and (D) latter (P = .002) groups. The Wilcoxon matched-pair signed-rank test was used to compare the median JAK2 V617F allele burden for the comparisons.